Margin
SECURE PRODUCT EXPERIENCE
Preparing XZMargin…
Loading the next view with the same secure workspace experience.
● Demo modeSign in
INTELLIGENCE / PHARMA SAMPLE
Pharma profitability overview.
Explore the decisions behind the numbers in a dashboard-style preview. Illustrative financial analysis, not a review of any real company's accounts.
REPORT STATUS Illustration readySource: synthetic examplePeriod: demonstration data
DEMO REPORT 01 / 04
◆ SAMPLE WORKSPACE Figures are hypothetical and for product demonstration only; margin gaps are not proven losses or recoverable savings.
PERFORMANCE EXPLORER
Where the margin moves
Selected product categories · illustrative contribution margins
EXECUTIVE SIGNAL
Review before acting
₹6.8L
Expiry-risk stockbatch-level review. An evidence-led review separates the sales number from the actual order contribution.
View priority decisions →HOW TO READ THISFind the issue → validate the source cost → decide what to change.
PRODUCT INTELLIGENCE
Profitability by product line
Selected examples, not the entire transaction ledger
| Product / pack | Revenue | Margin | Review status |
|---|---|---|---|
| ▣Cardio-X 10mg · Pack 30 | ₹82.4L | 17.8% | Healthy |
| ▣Neurocare 50mg · Pack 10 | ₹64.7L | 8.1% | Review pricing |
| ▣Onco-A 100mg · Vial | ₹51.3L | 5.4% | Cost pressure |
| ▣Respira-D · Pack 20 | ₹43.9L | 19.6% | Push more |
PRIORITY ACTION CENTER
What deserves attention?
Ranked illustrative review scenarios. Amounts are exposures or modelled opportunities, not guaranteed recovery.
01 / REVIEW
Reprice export orders where packaging + purchase cost moved faster
₹3.2L
Illustrative impact under assumptions
02 / REVIEW
Review expiry-risk batch B-118 before next purchase cycle
₹2.6L
Illustrative impact under assumptions
03 / REVIEW
Reduce slow-moving stock at Unit 2
₹4.9L
Illustrative impact under assumptions
INVOICE EVIDENCE · ILLUSTRATIVE
The invoices behind a finding
Synthetic invoice lines for: Reprice export orders where packaging + purchase cost moved faster. Real findings list the invoices from your own file.
| Invoice | Date | Customer | Item | Qty | Rate | Value |
|---|---|---|---|---|---|---|
| INV-S-1042 | 04 Sep 2026 | Sample Export Trading FZE | Neurocare 50mg · Pack 10 | 1,200 | ₹540 | ₹6,48,000 |
| INV-S-1057 | 11 Sep 2026 | Sample Pharma Exports Ltd | Onco-A 100mg · Vial | 300 | ₹2,150 | ₹6,45,000 |
| INV-S-1068 | 19 Sep 2026 | Sample Gulf Distributors | Neurocare 50mg · Pack 10 | 800 | ₹530 | ₹4,24,000 |
Synthetic data. Customers and invoice numbers are made up.
BUSINESS CONTEXT
What the analysis considers
Manufacturing unitBaddi 18.4% vs Vapi 10.3%
Export marketGCC vs East Africa contribution
Batch / expiryPrioritise stock before expiry
METHODOLOGY NOTE
Evidence before estimates.
Real XZMargin analysis depends on uploaded transaction and stock evidence. Missing purchase cost, direct expenses or stock movement must be disclosed; they should never be silently invented.
Net sales− goods cost − direct costs = contribution
Scenario-level figures are authored sample data; the page is not a live import or audit of a real business.FROM SAMPLE TO YOUR NUMBERS
Your existing accounting system. Better commercial visibility.
Start with CSV/XLSX from Tally, BUSY, Excel or another compatible source. You control when to import data; this preview never asks for credentials.